M
Merav Lidar
Researcher at Tel Aviv University
Publications - 160
Citations - 3665
Merav Lidar is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Familial Mediterranean fever & MEFV. The author has an hindex of 32, co-authored 146 publications receiving 2908 citations. Previous affiliations of Merav Lidar include Sheba Medical Center.
Papers
More filters
Journal ArticleDOI
Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination
Abdulla Watad,Gabriele De Marco,Hussein Mahajna,Hussein Mahajna,Amit Druyan,Amit Druyan,Mailam Eltity,Nizar Hijazi,A. Haddad,Muna Elias,Devy Zisman,Mohammad E. Naffaa,Michal Brodavka,Michal Brodavka,Yael Cohen,Yael Cohen,Arsalan Abu-Much,Muhanad Abu Elhija,Charlie Bridgewood,Pnina Langevitz,Pnina Langevitz,Joanna McLorinan,Nicola Luigi Bragazzi,Helena Marzo-Ortega,Merav Lidar,Merav Lidar,Cassandra Calabrese,Leonard H. Calabrese,Edward M Vital,Yehuda Shoenfeld,Yehuda Shoenfeld,Howard Amital,Howard Amital,Dennis McGonagle +33 more
TL;DR: In this paper, the authors evaluated 28 cases of immune-mediated disease flare or new disease onset within 28-days of SARS-CoV-2 vaccination at five large tertiary centres in countries with early vaccination adoption, three in Israel, one in UK, and one in USA.
Journal ArticleDOI
The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.
TL;DR: Overall, disease severity and the development of amyloidosis in FMF are differentially affected by genetic variations within and outside the MEFV gene.
Journal ArticleDOI
Colchicine nonresponsiveness in familial mediterranean fever : Clinical, genetic, pharmacokinetic, and socioeconomic characterization
Merav Lidar,Jean-Michel Scherrmann,Yael Shinar,Angela Chetrit,Elisabeth Niel,Ruth Gershoni-Baruch,Pnina Langevitz,Avi Livneh +7 more
TL;DR: Colchicine treatment failure in FMF is associated with inadequate colchicines MNC concentration, probably resulting from a genetic defect unrelated to the underlying FMF.
Journal ArticleDOI
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Merav Lidar,Merav Lidar,Eitan Giat,Daniela Garelick,Yuval Horowitz,Howard Amital,Yael Steinberg-Silman,Jacob Schachter,Ronnie Shapira-Frommer,Gal Markel,Gal Markel +10 more
TL;DR: It is shown that rheumatic iAE are part of the side effect profile of ICIs and require heightened awareness as these therapies are becoming the standard of care for various malignancies.
Journal ArticleDOI
Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial.
Ilan Ben-Zvi,Olga Kukuy,Eitan Giat,Elon Pras,Olga Feld,Shaye Kivity,Oleg Perski,Gil Bornstein,Chagai Grossman,Gil Harari,Merav Lidar,Avi Livneh +11 more
TL;DR: Treatment with anakinra, an interleukin‐1–blocking agent, prevented FMF attacks in those with colchicine‐resistant FMF, using a randomized controlled trial.